DK0549581T3 - Grundstruktur-muterede antistoffer og deres fremstilling - Google Patents
Grundstruktur-muterede antistoffer og deres fremstillingInfo
- Publication number
- DK0549581T3 DK0549581T3 DK91907669.5T DK91907669T DK0549581T3 DK 0549581 T3 DK0549581 T3 DK 0549581T3 DK 91907669 T DK91907669 T DK 91907669T DK 0549581 T3 DK0549581 T3 DK 0549581T3
- Authority
- DK
- Denmark
- Prior art keywords
- production
- basic structure
- derived
- framework
- mutated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909020282A GB9020282D0 (en) | 1990-09-17 | 1990-09-17 | Altered antibodies and their preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0549581T3 true DK0549581T3 (da) | 1997-05-26 |
Family
ID=10682322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK91907669.5T DK0549581T3 (da) | 1990-09-17 | 1991-09-16 | Grundstruktur-muterede antistoffer og deres fremstilling |
Country Status (20)
Country | Link |
---|---|
US (5) | USRE46877E1 (de) |
EP (1) | EP0549581B2 (de) |
JP (1) | JPH06502762A (de) |
KR (1) | KR100217212B1 (de) |
AT (1) | ATE148172T1 (de) |
AU (1) | AU660151B2 (de) |
CA (1) | CA2091769C (de) |
DE (1) | DE69124387T3 (de) |
DK (1) | DK0549581T3 (de) |
ES (1) | ES2097808T3 (de) |
GB (1) | GB9020282D0 (de) |
GR (1) | GR3023252T3 (de) |
ID (1) | ID1044B (de) |
IE (1) | IE913257A1 (de) |
IL (1) | IL99499A (de) |
MX (1) | MX9101117A (de) |
MY (1) | MY111682A (de) |
NZ (1) | NZ239826A (de) |
WO (1) | WO1992005274A1 (de) |
ZA (1) | ZA917407B (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
GB9206422D0 (en) * | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
DE69627665T2 (de) * | 1995-05-18 | 2004-02-19 | Ortho-Mcneil Pharmaceutical, Inc. | Induktion von immunologischer toleranz unter verwendung von nicht-zellmengeverringernden anti-cd4-antikoepern |
US6228360B1 (en) * | 1998-08-19 | 2001-05-08 | Ajinomoto Co., Inc. | Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody |
US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
CA2443437A1 (en) * | 2001-05-18 | 2002-11-28 | Boehringer Ingelheim International Gmbh | Antibodies specific for cd44v6 |
GB2376466A (en) * | 2001-06-14 | 2002-12-18 | Mark Frewin | TRX1 antibody |
US8165535B2 (en) * | 2006-06-04 | 2012-04-24 | Samsung Electro-Mechanics | Systems, methods and apparatuses for complementary metal oxide semiconductor (CMOS) antenna switches using switched resonators |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US7575893B2 (en) | 2003-01-23 | 2009-08-18 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
ES2484340T3 (es) | 2003-12-05 | 2014-08-11 | Multimmune Gmbh | Anticuerpos anti hsp70 terapéuticos y diagnósticos |
CA2574881C (en) * | 2004-08-04 | 2013-01-08 | Amgen Inc. | Antibodies to dkk-1 |
JP2009504136A (ja) * | 2005-05-24 | 2009-02-05 | アベスタゲン リミテッド | 慢性リンパ性白血病治療のためのcd52に対するモノクローナル抗体産生のための組み換え法 |
AU2008203703C1 (en) | 2007-01-05 | 2014-04-03 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
US8519106B2 (en) | 2007-03-13 | 2013-08-27 | University Of Zurich | Monoclonal human tumor-specific antibody |
EP1997830A1 (de) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung |
US20100239570A1 (en) | 2007-09-13 | 2010-09-23 | Roger Nitsch | Moncolonal amyloid beta (abeta) - specific antibody and uses thereof |
US9005963B2 (en) | 2008-10-14 | 2015-04-14 | Ablynx N.V. | Amino acid sequences directed against cellular receptors for viruses and bacteria |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
ES2595376T3 (es) | 2009-12-10 | 2016-12-29 | Regeneron Pharmaceuticals, Inc. | Ratones que producen anticuerpos de cadena pesada |
DE202011103324U1 (de) | 2011-07-12 | 2012-01-02 | Nekonal S.A.R.L. | Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten |
DK2758433T3 (en) | 2011-09-19 | 2018-01-15 | Axon Neuroscience Se | PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY OF ALZHEIMER'S DISEASE |
JP6316195B2 (ja) | 2011-10-26 | 2018-04-25 | エランコ ティーアゲズンタイト アーゲー | モノクローナル抗体および使用の方法 |
WO2013093122A2 (en) | 2011-12-23 | 2013-06-27 | Phenoquest Ag | Antibodies for the treatment and diagnosis of affective and anxiety disorders |
PL2797951T3 (pl) | 2011-12-28 | 2018-07-31 | Immunoqure Ag | Sposób izolacji ludzkich przeciwciał |
US10112995B2 (en) | 2013-07-03 | 2018-10-30 | Immunoqure Ag | Human anti-IFN-α antibodies |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
WO2022153212A1 (en) | 2021-01-13 | 2022-07-21 | Axon Neuroscience Se | Antibodies neutralizing sars-cov-2 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4652447A (en) | 1979-04-26 | 1987-03-24 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human helper T cells |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4695459A (en) | 1984-12-26 | 1987-09-22 | The Board Of Trustees Of Leland Stanford Junior University | Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells |
US4681760A (en) | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
AU625613B2 (en) | 1988-01-05 | 1992-07-16 | Novartis Ag | Novel chimeric antibodies |
JP2646007B2 (ja) | 1988-01-30 | 1997-08-25 | 財団法人 化学及血清療法研究所 | 抗hiv抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗hivキメラ抗体ならびにその製法 |
AU618989B2 (en) | 1988-02-12 | 1992-01-16 | British Technology Group Limited | Improvements in or relating to antibodies |
KR900700134A (ko) | 1988-04-15 | 1990-08-11 | 원본미기재 | Il-2 수용체-특이적 키메릭 항체 |
EP0365209A3 (de) | 1988-10-17 | 1990-07-25 | Becton, Dickinson and Company | Aminosäuresequenz des Anti-leu 3a |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
EP0380018B1 (de) | 1989-01-23 | 1995-07-19 | Abbott Laboratories | Monoklonale Antikörper von Ratten gegen menschliche Antigene und Verfahren zu deren Herstellung |
CA2018248A1 (en) * | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
JPH0353894A (ja) | 1989-07-21 | 1991-03-07 | Calpis Food Ind Co Ltd:The | 抗ヒトcd4ペプチドに対するモノクローナル抗体 |
GB8925590D0 (en) | 1989-11-13 | 1990-01-04 | Central Blood Lab Authority | Monoclonal antibodies |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
GB9022543D0 (en) * | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
LU91067I2 (fr) * | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
GB9125979D0 (en) * | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
-
1990
- 1990-09-17 GB GB909020282A patent/GB9020282D0/en active Pending
-
1991
- 1991-09-16 JP JP3516449A patent/JPH06502762A/ja active Pending
- 1991-09-16 EP EP91907669A patent/EP0549581B2/de not_active Expired - Lifetime
- 1991-09-16 US US13/683,113 patent/USRE46877E1/en not_active Expired - Lifetime
- 1991-09-16 US US11/493,016 patent/USRE43898E1/en not_active Expired - Lifetime
- 1991-09-16 CA CA002091769A patent/CA2091769C/en not_active Expired - Lifetime
- 1991-09-16 DE DE69124387T patent/DE69124387T3/de not_active Expired - Lifetime
- 1991-09-16 AT AT91907669T patent/ATE148172T1/de not_active IP Right Cessation
- 1991-09-16 WO PCT/GB1991/001578 patent/WO1992005274A1/en active IP Right Grant
- 1991-09-16 US US08/030,175 patent/US6767996B1/en not_active Ceased
- 1991-09-16 IE IE325791A patent/IE913257A1/en unknown
- 1991-09-16 IL IL99499A patent/IL99499A/en not_active IP Right Cessation
- 1991-09-16 AU AU85088/91A patent/AU660151B2/en not_active Expired
- 1991-09-16 DK DK91907669.5T patent/DK0549581T3/da active
- 1991-09-16 KR KR1019930700786A patent/KR100217212B1/ko not_active IP Right Cessation
- 1991-09-16 ES ES91907669T patent/ES2097808T3/es not_active Expired - Lifetime
- 1991-09-17 NZ NZ239826A patent/NZ239826A/xx not_active IP Right Cessation
- 1991-09-17 MY MYPI91001686A patent/MY111682A/en unknown
- 1991-09-17 MX MX9101117A patent/MX9101117A/es unknown
- 1991-09-17 ZA ZA917407A patent/ZA917407B/xx unknown
- 1991-10-17 ID IDP61891A patent/ID1044B/id unknown
-
1995
- 1995-06-02 US US08/459,655 patent/US7098006B1/en not_active Expired - Lifetime
-
1997
- 1997-04-22 GR GR970400917T patent/GR3023252T3/el unknown
-
2005
- 2005-04-26 US US11/114,233 patent/US20070212753A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2091769A1 (en) | 1992-03-18 |
WO1992005274A1 (en) | 1992-04-02 |
NZ239826A (en) | 1992-12-23 |
JPH06502762A (ja) | 1994-03-31 |
GR3023252T3 (en) | 1997-07-30 |
DE69124387T3 (de) | 2011-02-17 |
IE913257A1 (en) | 1992-02-25 |
IL99499A0 (en) | 1992-08-18 |
IL99499A (en) | 2006-08-20 |
EP0549581B2 (de) | 2010-04-28 |
US20070212753A1 (en) | 2007-09-13 |
MX9101117A (es) | 1992-05-04 |
USRE43898E1 (en) | 2013-01-01 |
ZA917407B (en) | 1992-06-24 |
USRE46877E1 (en) | 2018-05-29 |
KR100217212B1 (ko) | 1999-10-01 |
AU660151B2 (en) | 1995-06-15 |
DE69124387D1 (de) | 1997-03-06 |
KR930702535A (ko) | 1993-09-09 |
US6767996B1 (en) | 2004-07-27 |
EP0549581A1 (de) | 1993-07-07 |
CA2091769C (en) | 2002-07-23 |
ID1044B (id) | 1996-10-28 |
US7098006B1 (en) | 2006-08-29 |
ES2097808T3 (es) | 1997-04-16 |
DE69124387T2 (de) | 1997-05-15 |
EP0549581B1 (de) | 1997-01-22 |
GB9020282D0 (en) | 1990-10-31 |
ATE148172T1 (de) | 1997-02-15 |
AU8508891A (en) | 1992-04-15 |
MY111682A (en) | 2000-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0549581T3 (da) | Grundstruktur-muterede antistoffer og deres fremstilling | |
DK0626390T3 (da) | Humaniserede antistoffer | |
DE69111596D1 (de) | Verwendung von zwitterionen zur mobilisierung isoelektrisch fokussierter ampholytzonen. | |
DE3581578D1 (de) | Antikoerper, herstellung und verwendung. | |
PL313260A1 (en) | Monoclonal antibodies having properties making them able to cause apoptosis | |
AR240175A1 (es) | Una linea celular producida por tecnica de hibridoma y un anticuerpo monoclonal derivado de la misma. | |
DE59010826D1 (de) | Monoklonale Antikörper (MAK) gegen tumorassoziierte Antigene, ihre Herstellung und Verwendung | |
DE3885355D1 (de) | Monoklonale Antikörper. | |
ATE48037T1 (de) | Verfahren und reagenz zur verwendung zur bestimmung von pivka-ii. | |
ATE206621T1 (de) | Il-8 antagonisten zur behandlung von asthma | |
DK26587D0 (da) | Monoklonalt antistof, maalemetode for glucosyleret protein ved anvendelse af det monoklonale antistofog kit omfattende dette | |
DE3579573D1 (de) | Logisches gatter mit "verdrahteter" und-funktion-eingangsstufe unter verwendung von feldeffekttransistoren. | |
DE3585049D1 (de) | Monoklonale antikoerper. | |
EP0299354A3 (en) | Monoclonal antibodies against protein e7 of the human papilloma virus type 16, their production process and their use | |
IT1184668B (it) | Linfochina,suo anticorpo specifico monoclonale e relativo procedimento di produzione | |
DE3580524D1 (de) | Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen. | |
NO893818L (no) | Produksjon og anvendelse av hybride, monoklonale antistoffer. | |
DE3785175D1 (de) | A-assoziierte h-antigene, spezifische monoklonale antikoerper und methoden zu deren verwendung zur blutgruppenbestimmung. | |
DE69023717D1 (de) | Monoklonaler Antikörper. | |
DE69111429D1 (de) | Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen. | |
MY104917A (en) | Monoclonal antibodies and methods for diagnosis of phytophora infection | |
ATE92102T1 (de) | Genfragmente, die die variable region eines anti- hiv-antikoerpers codieren, von diesen exprimierte chimaere anti-hiv-antikoerper und verfahren zu deren herstellung. | |
IT8821547A0 (it) | Metodo immunologico per la determinazione di anticorpi anti antigeni di microorganismi, mediante anticorpi antiidiotipo e mezzi adatti allo scopo. |